Allogeneic 0 10 0 10 B-treatment
hematopoietic 11 24 11 24 I-treatment
cell 25 29 25 29 I-treatment
transplant 30 40 30 40 I-treatment
for 41 44 41 44 O
hematologic 45 56 45 56 B-cancer
malignancy 57 67 57 67 I-cancer
( 68 69 68 69 O
i.e. 69 73 69 73 O
leukemia 74 82 74 82 B-cancer
, 82 83 82 83 O
lymphoma 84 92 84 92 B-cancer
including 93 102 93 102 O
ALL 103 106 103 106 B-cancer
, 106 107 106 107 O
AML 108 111 108 111 B-cancer
, 111 112 111 112 O
CML 113 116 113 116 B-cancer
, 116 117 116 117 O
NHL 118 121 118 121 B-cancer
, 121 122 121 122 O
HL 123 125 123 125 O
) 125 126 125 126 O
in 127 129 127 129 O
complete 130 138 130 138 O
remission 139 148 139 148 O
; 148 149 148 149 O
myelodysplastic 150 165 150 165 B-cancer
syndrome 166 174 166 174 I-cancer
( 175 176 175 176 O
active 176 182 176 182 O
dysplasia 183 192 183 192 B-cancer
and/or 193 199 193 199 O
blasts 200 206 200 206 B-cancer
are 207 210 207 210 O
permitted 211 220 211 220 O
, 220 221 220 221 O
but 222 225 222 225 O
must 226 230 226 230 O
not 231 234 231 234 O
have 235 239 235 239 O
active 240 246 240 246 O
leukemia 247 255 247 255 O
) 255 256 255 256 O
or 257 259 257 259 O
idiopathic 260 270 260 270 B-chronic_disease
severe 271 277 271 277 I-chronic_disease
aplastic 278 286 278 286 I-chronic_disease
anemia 287 293 287 293 I-chronic_disease
( 294 295 294 295 I-chronic_disease
SAA 295 298 295 298 I-chronic_disease
) 298 299 298 299 I-chronic_disease

Clinically 0 10 300 310 O
significant 11 22 311 322 O
fractures 23 32 323 332 O
as 33 35 333 335 O
defined 36 43 336 343 O
by 44 46 344 346 O
ISCD 47 51 347 351 O
( 52 53 352 353 O
a 53 54 353 354 O
long 55 59 355 359 O
bone 60 64 360 364 O
fracture 65 73 365 373 O
of 74 76 374 376 O
the 77 80 377 380 O
lower 81 86 381 386 O
extremities 87 98 387 398 O
, 98 99 398 399 O
vertebral 100 109 400 409 O
compression 110 121 410 421 O
fracture 122 130 422 430 O
, 130 131 430 431 O
or 132 134 432 434 O
two 135 138 435 438 O
or 139 141 439 441 O
more 142 146 442 446 O
long 147 151 447 451 O
bone 152 156 452 456 O
fractures 157 166 457 466 O
of 167 169 467 469 O
the 170 173 470 473 O
upper 174 179 474 479 O
extremities 180 191 480 491 O
) 191 192 491 492 O
( 193 194 493 494 O
88,89 194 199 494 499 O
) 199 200 499 500 O
indicated 201 210 501 510 O
by 211 213 511 513 O
a 214 215 514 515 O
cast 216 220 516 520 O
or 221 223 521 523 O
a 224 225 524 525 O
spine 226 231 526 531 O
x 232 233 532 533 B-treatment
- 233 234 533 534 I-treatment
ray 234 237 534 537 I-treatment
within 238 244 538 544 O
the 245 248 545 548 O
last 249 253 549 553 B-upper_bound
2 254 255 554 555 I-upper_bound
weeks 256 261 556 561 I-upper_bound

Hereditary 0 10 562 572 O
metabolic 11 20 573 582 B-chronic_disease
bone 21 25 583 587 I-chronic_disease
disease 26 33 588 595 I-chronic_disease
or 34 36 596 598 O
skeletal 37 45 599 607 B-chronic_disease
dysplasia 46 55 608 617 I-chronic_disease
( 56 57 618 619 O
e.g. 57 61 619 623 O
, 61 62 623 624 O
osteopetrosis 63 76 625 638 B-chronic_disease
or 77 79 639 641 O
OI 80 82 642 644 B-chronic_disease
) 82 83 644 645 O
or 84 86 646 648 O
primary 87 94 649 656 B-chronic_disease
hyperparathyroidism 95 114 657 676 I-chronic_disease

History 0 7 677 684 O
of 8 10 685 687 O
a 11 12 688 689 O
primary 13 20 690 697 O
bone 21 25 698 702 B-cancer
malignancy 26 36 703 713 I-cancer
involving 37 46 714 723 O
the 47 50 724 727 O
lumbar 51 57 728 734 O
spine 58 63 735 740 O

Impending 0 9 741 750 O
invasive 10 18 751 759 B-treatment
dental 19 25 760 766 I-treatment
procedure 26 35 767 776 I-treatment
that 36 40 777 781 O
would 41 46 782 787 O
be 47 49 788 790 O
expected 50 58 791 799 O
to 59 61 800 802 O
occur 62 67 803 808 O
during 68 74 809 815 O
study 75 80 816 821 O
participation 81 94 822 835 O
( 95 96 836 837 O
through 96 103 837 844 O
Day 104 107 845 848 O
360 108 111 849 852 O
) 111 112 852 853 O

Known 0 5 854 859 O
or 6 8 860 862 O
suspected 9 18 863 872 O
allergy 19 26 873 880 O
to 27 29 881 883 O
pamidronate 30 41 884 895 B-allergy_name
or 42 44 896 898 O
related 45 52 899 906 O
products 53 61 907 915 O

Male 0 4 916 920 B-gender

Myeloablative 0 13 921 934 B-treatment
preparative 14 25 935 946 I-treatment
regimen 26 33 947 954 I-treatment
( 34 35 955 956 O
for 35 38 956 959 O
SAA 39 42 960 963 B-chronic_disease
any 43 46 964 967 O
conditioning 47 59 968 980 O
therapy 60 67 981 988 B-treatment
allowed 68 75 989 996 O
) 75 76 996 997 O

Non 0 3 998 1001 B-chronic_disease
- 3 4 1001 1002 I-chronic_disease
malignant 4 13 1002 1011 I-chronic_disease
diseases 14 22 1012 1020 I-chronic_disease
including 23 32 1021 1030 O
idiopathic 33 43 1031 1041 B-chronic_disease
severe 44 50 1042 1048 I-chronic_disease
aplastic 51 59 1049 1057 I-chronic_disease
anemia 60 66 1058 1064 I-chronic_disease
( 67 68 1065 1066 I-chronic_disease
SAA 68 71 1066 1069 I-chronic_disease
) 71 72 1069 1070 I-chronic_disease
and 73 76 1071 1074 O
other 77 82 1075 1080 O
bone 83 87 1081 1085 B-chronic_disease
marrow 88 94 1086 1092 I-chronic_disease
failure 95 102 1093 1100 I-chronic_disease
disorders 103 112 1101 1110 I-chronic_disease
, 112 113 1110 1111 O
hemoglobinopathies 114 132 1112 1130 B-chronic_disease
, 132 133 1130 1131 O
adrenoleukodystrophy 134 154 1132 1152 B-chronic_disease
, 154 155 1152 1153 O
immune 156 162 1154 1160 B-chronic_disease
deficiencies 163 175 1161 1173 I-chronic_disease
/ 175 176 1173 1174 O
dysregulation 176 189 1174 1187 B-chronic_disease
disorders 190 199 1188 1197 I-chronic_disease
who 200 203 1198 1201 O
will 204 208 1202 1206 O
be 209 211 1207 1209 O
receiving 212 221 1210 1219 O
myeloablative 222 235 1220 1233 B-treatment
or 236 238 1234 1236 O
reduced 239 246 1237 1244 O
toxicity 247 255 1245 1253 O
preparative 256 267 1254 1265 O
regimens 268 276 1266 1274 O
that 277 281 1275 1279 O
meet 282 286 1280 1284 O
the 287 290 1285 1288 O
following 291 300 1289 1298 O
criteria 301 309 1299 1307 O

Other 0 5 1308 1313 O
indications 6 17 1314 1325 O
for 18 21 1326 1329 O
HCT 22 25 1330 1333 O
, 25 26 1333 1334 O
including 27 36 1335 1344 O
Fanconi 37 44 1345 1352 B-chronic_disease
anemia 45 51 1353 1359 I-chronic_disease
, 51 52 1359 1360 O
other 53 58 1361 1366 O
form 59 63 1367 1371 O
of 64 66 1372 1374 O
inherited 67 76 1375 1384 O
bone 77 81 1385 1389 B-chronic_disease
marrow 82 88 1390 1396 I-chronic_disease
failure 89 96 1397 1404 I-chronic_disease
diseases 97 105 1405 1413 I-chronic_disease
, 105 106 1413 1414 O
metabolic 107 116 1415 1424 B-chronic_disease
disorder 117 125 1425 1433 I-chronic_disease
, 125 126 1433 1434 O
hemoglobinopathy 127 143 1435 1451 B-chronic_disease
, 143 144 1451 1452 O
or 145 147 1453 1455 O
immune 148 154 1456 1462 B-chronic_disease
deficiency 155 165 1463 1473 I-chronic_disease

Patients 0 8 1474 1482 O
with 9 13 1483 1487 O
severe 14 20 1488 1494 O
aplastic 21 29 1495 1503 B-chronic_disease
anemia 30 36 1504 1510 I-chronic_disease
are 37 40 1511 1514 O
eligible 41 49 1515 1523 O
regardless 50 60 1524 1534 O
of 61 63 1535 1537 O
conditioning 64 76 1538 1550 B-treatment
regimen 77 84 1551 1558 I-treatment

Planned 0 7 1559 1566 O
administration 8 22 1567 1581 O
of 23 25 1582 1584 O
an 26 28 1585 1587 O
investigational 29 44 1588 1603 B-treatment
study 45 50 1604 1609 I-treatment
drug 51 55 1610 1614 I-treatment
or 56 58 1615 1617 O
agent 59 64 1618 1623 O
that 65 69 1624 1628 O
either 70 76 1629 1635 O
can 77 80 1636 1639 O
interact 81 89 1640 1648 O
with 90 94 1649 1653 O
pamidronate 95 106 1654 1665 B-treatment
or 107 109 1666 1668 O
have 110 114 1669 1673 O
an 115 117 1674 1676 O
independent 118 129 1677 1688 O
effect 130 136 1689 1695 O
on 137 139 1696 1698 O
bone 140 144 1699 1703 O
mineral 145 152 1704 1711 O
density 153 160 1712 1719 O
within 161 167 1720 1726 O
the 168 171 1727 1730 O
4 172 173 1731 1732 B-upper_bound
weeks 174 179 1733 1738 I-upper_bound
prior 180 185 1739 1744 I-upper_bound
to 186 188 1745 1747 O
randomization 189 202 1748 1761 O
( 203 204 1762 1763 O
Day 204 207 1763 1766 B-lower_bound
90 208 210 1767 1769 I-lower_bound
) 210 211 1769 1770 O
or 212 214 1771 1773 O
planned 215 222 1774 1781 O
use 223 226 1782 1785 O
during 227 233 1786 1792 O
study 234 239 1793 1798 O
participation 240 253 1799 1812 O
( 254 255 1813 1814 O
Day 255 258 1814 1817 O
90 259 261 1818 1820 O
through 262 269 1821 1828 O
Day 270 273 1829 1832 B-upper_bound
360 274 277 1833 1836 I-upper_bound
) 277 278 1836 1837 O

Pregnancy 0 9 1838 1847 B-pregnancy
or 10 12 1848 1850 O
breastfeeding 13 26 1851 1864 O
- 27 28 1865 1866 O
menstruating 29 41 1867 1879 O
females 42 49 1880 1887 B-gender
must 50 54 1888 1892 O
have 55 59 1893 1897 O
a 60 61 1898 1899 O
negative 62 70 1900 1908 B-pregnancy
pregnancy 71 80 1909 1918 I-pregnancy
test 81 85 1919 1923 O
prior 86 91 1924 1929 O
to 92 94 1930 1932 O
study 95 100 1933 1938 O
enrollment 101 111 1939 1949 O
and 112 115 1950 1953 O
agree 116 121 1954 1959 O
to 122 124 1960 1962 O
repeat 125 131 1963 1969 O
pregnancy 132 141 1970 1979 O
testing 142 149 1980 1987 O
and 150 153 1988 1991 O
contraception 154 167 1992 2005 O
use 168 171 2006 2009 O
per 172 175 2010 2013 O
protocol 176 184 2014 2022 O
as 185 187 2023 2025 O
pamidronate 188 199 2026 2037 B-treatment
is 200 202 2038 2040 O
Pregnancy 203 212 2041 2050 O
Category 213 221 2051 2059 O
D 222 223 2060 2061 O
- 224 225 2062 2063 O
positive 226 234 2064 2072 O
evidence 235 243 2073 2081 O
of 244 246 2082 2084 O
human 247 252 2085 2090 O
fetal 253 258 2091 2096 O
risk 259 263 2097 2101 O
based 264 269 2102 2107 O
on 270 272 2108 2110 O
adverse 273 280 2111 2118 O
reaction 281 289 2119 2127 O
data 290 294 2128 2132 O

Prior 0 5 2133 2138 O
and/or 6 12 2139 2145 O
planned 13 20 2146 2153 O
concomitant 21 32 2154 2165 B-treatment
medical 33 40 2166 2173 I-treatment
therapy 41 48 2174 2181 I-treatment
during 49 55 2182 2188 O
the 56 59 2189 2192 O
study 60 65 2193 2198 O
period 66 72 2199 2205 O
( 73 74 2206 2207 O
through 74 81 2207 2214 O
Day 82 85 2215 2218 B-upper_bound
360 86 89 2219 2222 I-upper_bound
post 90 94 2223 2227 B-treatment
- 94 95 2227 2228 I-treatment
HCT 95 98 2228 2231 I-treatment
) 98 99 2231 2232 O
with 100 104 2233 2237 O
other 105 110 2238 2243 O
bisphosphonates 111 126 2244 2259 B-treatment
, 126 127 2259 2260 O
Denosumab 128 137 2261 2270 B-treatment
, 137 138 2270 2271 O
or 139 141 2272 2274 O
Teriparatide 142 154 2275 2287 B-treatment

Renal 0 5 2288 2293 B-chronic_disease
insufficiency 6 19 2294 2307 I-chronic_disease
, 19 20 2307 2308 O
defined 21 28 2309 2316 O
as 29 31 2317 2319 O
creatinine 32 42 2320 2330 B-clinical_variable
level 43 48 2331 2336 I-clinical_variable
greater 49 56 2337 2344 O
than 57 61 2345 2349 O
the 62 65 2350 2353 O
upper 66 71 2354 2359 O
limit 72 77 2360 2365 O
of 78 80 2366 2368 O
normal 81 87 2369 2375 O
for 88 91 2376 2379 O
age 92 95 2380 2383 B-age

Subjects 0 8 2384 2392 O
who 9 12 2393 2396 O
turn 13 17 2397 2401 O
18 18 20 2402 2404 B-upper_bound
during 21 27 2405 2411 O
the 28 31 2412 2415 O
course 32 38 2416 2422 O
of 39 41 2423 2425 O
the 42 45 2426 2429 O
study 46 51 2430 2435 O
will 52 56 2436 2440 O
be 57 59 2441 2443 O
consented 60 69 2444 2453 O
at 70 72 2454 2456 O
that 73 77 2457 2461 O
time 78 82 2462 2466 O
of 83 85 2467 2469 O
their 86 91 2470 2475 O
next 92 96 2476 2480 O
visit 97 102 2481 2486 O
by 103 105 2487 2489 O
a 106 107 2490 2491 O
member 108 114 2492 2498 O
of 115 117 2499 2501 O
the 118 121 2502 2505 O
research 122 130 2506 2514 O
staff 131 136 2515 2520 O

These 0 5 2521 2526 O
also 6 10 2527 2531 O
include 11 18 2532 2539 O
chemotherapy 19 31 2540 2552 B-treatment
only 32 36 2553 2557 O
based 37 42 2558 2563 O
regimens 43 51 2564 2572 O
that 52 56 2573 2577 O
contain 57 64 2578 2585 O
myeloablative 65 78 2586 2599 O
doses 79 84 2600 2605 O
of 85 87 2606 2608 O
busulfan 88 96 2609 2617 B-treatment
( 97 98 2618 2619 O
> 98 99 2619 2620 O
8mg 99 102 2620 2623 B-lower_bound
/ 102 103 2623 2624 I-lower_bound
kg 103 105 2624 2626 I-lower_bound
) 105 106 2626 2627 O
or 107 109 2628 2630 O
treosulfan 110 120 2631 2641 B-treatment
without 121 128 2642 2649 O
TBI 129 132 2650 2653 O

female 0 6 2654 2660 B-gender

≥1 0 2 2661 2663 O
but 3 6 2664 2667 O
≤ 7 8 2668 2669 O
20 9 11 2670 2672 B-upper_bound
years 12 17 2673 2678 I-upper_bound
of 18 20 2679 2681 O
age 21 24 2682 2685 B-age
at 25 27 2686 2688 O
time 28 32 2689 2693 O
of 33 35 2694 2696 O
study 36 41 2697 2702 O
enrollment 42 52 2703 2713 O

